🚀 This integrated solution aims to enhance biopharma clients’ workflows from discovery to pre-clinical development.
💡 Together, they focus on creating innovative therapeutic antibodies, ensuring efficient and successful drug development paths.
Introduction:
Abzena, a global biopharmaceutical services company, has announced a strategic partnership with Mabqi, a France-based firm specializing in antibody discovery. This collaboration aims to integrate their respective strengths to provide an end-to-end solution for drug development, facilitating a seamless transition from discovery to pre-clinical stages.
- The partnership combines Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services.
- The objective is to streamline workflows for biopharmaceutical customers, enhancing the drug development process.
- Utilizing Mabqi’s LiteMab Antibody Discovery Studio, the collaboration aims to optimize hit screening and candidate selection.
- Abzena will contribute its expertise in cell line development, process development, and GMP manufacturing.
- The partnership is described as a significant step toward advancing antibody innovation, prioritizing integration and collaboration between both companies.
Conclusion:
This partnership between Abzena and Mabqi not only promises to accelerate the drug development process but also seeks to enhance the success rate of therapeutic candidates entering the clinic. The combination of their respective technologies and expertise is expected to bring about more efficient workflows, ultimately benefiting patients through faster access to innovative therapies.
